Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2016 / Cilt: 22 - Sayı: 5

Ratlarda Deneysel Siklofosfamid Toksikasyonunda Silimarin ve Curcuminin Koruyucu ve Antigenotoksik Etkileri

Protective and Antigenotoxic Effects of Silymarin and Curcumin in Experimental Cyclophosphamide Intoxication in Rats [1]

Pages
693–701
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present study established that both SLY and CUR are effective against the toxic effects of high doses of CP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to investigate the protective effects of silymarin (SLY) and curcumin (CUR), which have strong antioxidant properties, against the toxic effects of high dose of cyclophosphamide (CP) on the liver and kidneys of rats.
📊
Key Findings & Data:For this purpose, a total of 36 adult Wistar albino female rats at the weight of, 250±10 g were used.
💡
Conclusion & Impact:The present study established that both SLY and CUR are effective against the toxic effects of high doses of CP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to investigate the protective effects of silymarin (SLY) and curcumin (CUR), which have strong antioxidant properties, against the toxic effects of high dose of cyclophosphamide (CP) on the liver and kidneys of rats. For this purpose, a total of 36 adult Wistar albino female rats at the weight of, 250±10 g were used. Biochemical parameters were found to be significantly higher in the CP-only group than in the other groups. In the groups in which SLY and CUR were administered concurrently with CP, biochemical parameters were found to be significantly lower than in the CP-only group. In the SLY+CP and CUR+CP groups, biochemical parameters were correlated with the severity of histopathological findings. In genotoxic examination, the comet parameter levels in the SLY+CP and CUR+CP-treated groups were lower than those in the CP-treated group. The present study established that both SLY and CUR are effective against the toxic effects of high doses of CP.

Özet

Bu çalışmada, yüksek dozda siklofosfamid (CP) verilen ratların karaciğer ve böbrekler üzerindeki toksik etkilerine karşı kuvvetli antioksidan özellikleri bulunan silimarin (SLY) ve curcuminin (CUR) koruyucu etkileri araştırıldı. Bu amaçla çalışmada toplam 36 adet, ağırlıkları 250±10 gram olan erişkin Wistar albino ırkı dişi ratlar kullanıldı. Yalnızca CP verilen grupta biyokimyasal parametreler kontrol grubuna göre istatistiksel olarak anlamlı bir şekilde yüksek bulundu. CP ile birlikte eş zamanlı olarak SLY ve CUR verilen gruplarda biyokimyasal parametreler, yalnızca CP verilen gruba göre istatiksel olarak anlamlı bir şekilde düşük bulundu. Genotoksik incelemede comet parametreleri CP ile birlikte eş zamanlı SLY ve CUR verilen gruplarda ise yalnızca CP verilen gruba göre istatistiksel olarak anlamlı bir şekilde düşük bulundu. Çalışmada CP'nin toksik etkilerine karşı, kuvvetli antioksidan özelliklere sahip SLY ve CUR'un koruyucu alternatif birer kimyasal madde olarak kullanılabileceği görüldü.

🔖

Cite This Article

AVCI, H., SEKKİN, S., BOYACIOĞLU, M., AKŞİT, H., TUNCA, R., EPİKMEN, E. T., BİRİNCİOĞLU, S. S. (2016). Ratlarda Deneysel Siklofosfamid Toksikasyonunda Silimarin ve Curcuminin Koruyucu ve Antigenotoksik Etkileri. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 22 - Sayı: 5, 693–701. https://ajindex.com/articles/273607

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Dollery C: Cyclophosphamide. In, Dollery C (Ed): Therapeutic Drugs. 354, Churchill Livingstone, Edinburg, 1999.
  2. McCarroll N, Keshava N, Cimino M, Chu M, Dearfield K, Keshava C, Kligerman A, Owen R, Protzel A, Putzrath R, Schoeny R: An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide. Environ Mol Mutagen, 49, 117-131, 2008. DOI: 10.1002 /em.20372 Senthilkumar S, Yogeeta SK, Subashini R, Devaki T: Attenuation of cyclophosphamide induced toxicity by squalene in experimental rats. Chem Biol Interact, 160, 225-260, 2006. DOI: 10.1016/j.cbi.2006.02.004 Bjelogrlic SK, Radic J, Jovic V, Radulovic S: Activitiy of d,I-?- tocopherol (vitamin E) against cardiotoxicity induced by doxorubucin and doxorubicin with cyclophosphamide in mice. Basic Clinic Pharmacol Toxicol, 97, 311-319, 2005. DOI: 10.1111/j.1742-7843.2005.pto_166.x Ceribaşı AO, Turk G, Sonmez M, Sakin F, Ateşşahin A: Toxic effect of cyclophosphamide on sperm morphology, testicular histology and blood oxidant-antioxidant balance, and protective roles of lycopene and ellagic acid. Basic Clin Pharmacol Toxicol, 107, 730-736, 2010. DOI: 10.1111/j.1742- 2010.00571.x Kren V, Walterova D: Silybin and silymarin-new effects and applications. Biomed Papers, 149, 29-41, 2005. Arafa HM: Uroprotective effects of curcumin in cyclophosphamide- induced haemorrhagic cystitis paradigm. Basic Clin Pharmacol Toxicol,, 393-399, 2009. DOI: 10.1111/j.1742-7843.2009.00379.x Garcia-Nino WR, Pedraza-Chaverri J: Protective effect of curcumin against heavy metals-induced liver damage. Food Chem Toxicol, 69, 182-, 2014. DOI: 10.1016/j.fct.2014.04.016 Hamid AA, Aiyelaagbe OO, Usman LA, Ameen OM, Lawal A: Antioxidants: İts medicinal and pharmacological applications. Afr J Pure Appl Chem, 48, 142-151, 2010.
  3. Ding TM, Tian SJ, Zhang ZX, Gu DZ, Chen YF, Shi, YH, Sun ZP: Determination of active component in silymarin by RP-LC and LC/MS. J Pharm Biomed Anal, 26, 155-61, 2001. DOI:10.1016/S0731-7085(01)00364-8.
  4. Flora K, Hahn M, Rosen H, Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol, 93, 139-143, 1998.
  5. Radko L, Cybulski W: Application of silymarin in human and animal medicine. J Pre Clin Clin Res, 1, 22-26, 2007.
  6. Sharma RA, Gescher AJ, Steward WP: Curcumin: The story so far. Eur J Cancer, 41, 1955-1968, 2005. DOI: 10.1016/j.ejca.2005.05.009 Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs, 61, 2035-2063